$2.93
5.02% yesterday
Nasdaq, May 20, 10:01 pm CET
ISIN
US8776191061
Symbol
TSHA
Sector
Industry

Taysha Gene Therapies Inc Stock price

$2.93
+1.48 102.07% 1M
+0.92 45.77% 6M
+1.20 69.36% YTD
-0.16 5.18% 1Y
+0.16 5.78% 3Y
-17.07 85.35% 5Y
-17.07 85.35% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.14 5.02%
ISIN
US8776191061
Symbol
TSHA
Sector
Industry

Key metrics

Market capitalization $628.96m
Enterprise Value $573.95m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 79.49
P/S ratio (TTM) P/S ratio 87.11
P/B ratio (TTM) P/B ratio 10.91
Revenue growth (TTM) Revenue growth -48.97%
Revenue (TTM) Revenue $7.22m
EBIT (operating result TTM) EBIT $-83.71m
Free Cash Flow (TTM) Free Cash Flow $-84.04m
Cash position $117.04m
EPS (TTM) EPS $-0.36
P/E forward negative
P/S forward 88.03
EV/Sales forward 80.33
Short interest 14.78%
Show more

Is Taysha Gene Therapies Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Taysha Gene Therapies Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Taysha Gene Therapies Inc forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Taysha Gene Therapies Inc forecast:

Buy
100%

Financial data from Taysha Gene Therapies Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7.22 7.22
49% 49%
100%
- Direct Costs 1.19 1.19
31% 31%
16%
6.04 6.04
51% 51%
84%
- Selling and Administrative Expenses 28 28
11% 11%
383%
- Research and Development Expense 61 61
6% 6%
844%
-83 -83
7% 7%
-1,143%
- Depreciation and Amortization 1.19 1.19
31% 31%
16%
EBIT (Operating Income) EBIT -84 -84
6% 6%
-1,159%
Net Profit -87 -87
26% 26%
-1,202%

In millions USD.

Don't miss a Thing! We will send you all news about Taysha Gene Therapies Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Taysha Gene Therapies Inc Stock News

Neutral
Seeking Alpha
5 days ago
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Hayleigh Collins - Senior Director, Corporate Communications and Investor Relations Sean P. Nolan - Chief Executive Officer Sukumar Nagendran - President and Head of R&D Kamran Alam - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Gil ...
Neutral
GlobeNewsWire
6 days ago
Obtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and next steps on enabling study initiation The FDA advised the Company to submit pivotal Part B trial protocol and associated statistical analysis plan as an amendment to the IND application, eliminating the need for formal end-of-phase meeting and potentially expediting study initiation and registr...
Neutral
GlobeNewsWire
12 days ago
DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2025, and host a corporate update confe...
More Taysha Gene Therapies Inc News

Company Profile

Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX.

Head office United States
CEO Sean Nolan
Employees 73
Founded 2019
Website www.tayshagtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today